LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

11.91 3.03

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.61

Max

12.3

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+164.88% upside

Dividenden
By Acuity
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-410M 938M
Vorige openingsprijs	8.88
Vorige sluitingsprijs	11.91

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 jun 2026, 23:56 UTC

Mondelez International shares declined in after-market trading, continuing a trend of three consecutive lower closes amid rising US Treasury yields and mixed economic signals.

12 jun 2026, 23:56 UTC

ETF Constituents

Macro News

The U.S. government acquired a 10% stake in USA Rare Earth, boosting investor sentiment for gold-mining firms and contributing to GDX's after-market gains.

12 jun 2026, 23:51 UTC

Asia equity markets rise on U.S.-Iran peace deal optimism, while U.S. producer prices signal persistent inflation ahead of Fed's interest rate decision.

12 jun 2026, 23:51 UTC

Global equity markets rise on U.S.-Iran peace deal optimism, while U.S. consumer sentiment improves amid easing inflation concerns.

12 jun 2026, 23:51 UTC

European equity markets rise on optimism for U.S.-Iran peace deal, despite mixed economic data from the UK and easing inflation in Germany.

12 jun 2026, 23:51 UTC

US equity markets show mixed performance amid geopolitical developments and rising inflation concerns, with key economic indicators and Fed decisions on the horizon.

12 jun 2026, 23:51 UTC

U.S. Industrial Production MoM data set for June 15, 2026, forecasts a cautious optimism with a predicted increase of 0.2% following April's strong performance.

12 jun 2026, 23:51 UTC

United Airlines Holdings Inc. shares declined in after-market trading, despite initial gains, amid rising U.S. Treasury yields and mixed economic signals.

12 jun 2026, 23:46 UTC

Take-Two Interactive shares are higher in after-market trading, reflecting a modest gain since Friday's close, though still below the 20-day moving average.

12 jun 2026, 23:46 UTC

JD.Com Inc. shares are higher in after-market trading, despite no specific news. The stock is near the lower end of its one-month range.

12 jun 2026, 23:46 UTC

ETF Constituents

iShares MSCI South Korea ETF rises in after-hours trading, supported by top holding SKM. Global equity markets remain mixed amid geopolitical developments.

12 jun 2026, 23:41 UTC

Check Point Software Technologies shares are higher in after-market hours, with trading notably strong despite no specific news driving the movement.

12 jun 2026, 23:41 UTC

U.S. Retail Sales Expected to Rise 0.5% in May Amid Cautious Consumer Sentiment and Geopolitical Tensions

12 jun 2026, 23:41 UTC

Cautious Optimism Surrounds Upcoming Canadian Housing Price Index Release Amidst Government Initiatives to Stabilize Market

12 jun 2026, 23:41 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in May Amid Economic Uncertainties and Inflation Pressures

12 jun 2026, 23:41 UTC

Biomarin Pharmaceutical shares traded lower in after-market hours, reflecting broader market dynamics amid rising bond yields and mixed equity performance.

12 jun 2026, 23:41 UTC

Fox Corp. shares are higher in after-market trading, reflecting a strong upward trajectory since Friday's close amid notable volatility.

12 jun 2026, 23:41 UTC

Baidu Inc. shares advanced in after-market trading, reaching a session high. The stock remains below its 20-day moving average amid rising bond yields.

12 jun 2026, 23:41 UTC

Correlated Moves

Bitcoin is trading lower on Friday, influenced by rising bond yields and a broader market decline in cryptocurrencies, including Ethereum.

12 jun 2026, 23:36 UTC

iShares Core U.S. Aggregate Bond ETF was roughly flat in after-market hours, maintaining stability near the upper end of its one-month trading range.

12 jun 2026, 23:36 UTC

Ross Stores Inc. shares declined in after-market trading, reflecting routine fluctuations. Broader market conditions were influenced by rising bond yields.

12 jun 2026, 23:36 UTC

The SPDR S&P Regional Banking ETF traded roughly flat in after-market hours, reflecting routine trading patterns amid mixed direction in broader U.S. stock indices.

12 jun 2026, 23:31 UTC

ETF Constituents

Macro News

Energy Select Sector SPDR Fund is lower in after-market hours, impacted by declines in Chevron and ExxonMobil, as broader market dynamics influence energy outlook.

12 jun 2026, 23:31 UTC

Market Awaits U.S. Building Permits Data Amid Mixed Sentiment and Economic Concerns Ahead of June 16 Release.

12 jun 2026, 23:31 UTC

Trip.com Group Ltd shares are higher in after-market trading, reaching a peak despite three consecutive lower daily finishes and being below its 20-day moving average.

12 jun 2026, 23:26 UTC

ETF Constituents

Macro News

The Industrial Select Sector SPDR Fund is trading higher in after-market hours, supported by positive industrial sector developments and gains among key holdings.

12 jun 2026, 23:26 UTC

ETF Constituents

The Materials Select Sector SPDR Fund is trading higher in after-market hours, supported by contributions from Freeport-McMoRan and Albemarle.

12 jun 2026, 23:22 UTC

Preliminary May 2026 Building Permits Data Set for Release Amid Cautious Optimism Following April's 5.8% Increase

12 jun 2026, 23:22 UTC

U.S. Export Prices Expected to Surge Amid Optimism from Geopolitical Developments and Recent Inflation Trends Ahead of June 16 Release

12 jun 2026, 23:22 UTC

Market Awaits May Housing Starts Data Amid Optimism for Real Estate Recovery and Government Initiatives on June 16, 2026.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

164.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 164.88%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.